|
|
||||||||||
|
J Am Coll Cardiol, 2004; 43:2177-2182, doi:10.1016/j.jacc.2004.02.052 © 2004 by the American College of Cardiology Foundation |


* UKB Berlin and Free University Berlin, Berlin, Germany
Orion Corporation, Espoo, Finland
Helsinki University Central Hospital, Helsinki, Finland
Manuscript received December 2, 2002; revised manuscript received January 18, 2004, accepted February 18, 2004.
* Reprint requests and correspondence: Steffen Sonntag, Department Internal Medicine, UKB Berlin, Academic Teaching Hospital, Free University Berlin, Warener Strasse 07, D-12683 Berlin, Germany.
steffen.sonntag{at}snafu.de
OBJECTIVES: We assessed the effects of levosimendan on left ventricular (LV) function in patients with acute myocardial ischemia and after coronary angioplasty.
BACKGROUND: The calcium sensitizer levosimendan improves the function of myocardium in experimental stunning.
METHODS: Twenty-four patients with an acute coronary syndrome underwent angioplasty followed by double-blinded, randomized treatment with 24 µg/kg of levosimendan (n = 16) or placebo (n = 8). Left ventricular pressures and volumes were recorded by cineventriculography and micromanometer-tipped catheters 10 min after angioplasty before drug administration (baseline) and 20 min after drug administration. Left ventricular function was assessed by the pressurevolume loop, and regional function analysis by the Slager method.
RESULTS: The number of hypokinetic segments decreased with levosimendan, from 8.9 ± 0.9 to 6.5 ± 1.1 (mean ± SEM), as compared with an increase from 7.8 ± 1.0 to 8.5 ± 1.1 with placebo (p = 0.016). A leftward and/or upward shift of the systolic part of the pressurevolume loop, indicating improved systolic function, was observed in eight of 16 of the levosimendan-treated and one of eight of the placebo patients (p = 0.178). In addition, the single-beat elastance was increased by levosimendan (p = 0.045). The pressurevolume area (p = 0.001), end-systolic pressure (p = 0.002), and volume index (p < 0.001) were decreased by levosimendan, but there was no change in the end-systolic pressurevolume ratio. End-diastolic pressure remained unchanged, whereas the end-diastolic volume index was decreased by levosimendan (p = 0.002). The time constant of isovolumic LV pressure fall decreased with levosimendan (p = 0.001).
CONCLUSIONS: Levosimendan improved the function of stunned myocardium without obvious impairment of diastolic function.
| ||||||||
This article has been cited by other articles:
![]() |
A. Tasouli, K. Papadopoulos, T. Antoniou, I. Kriaras, G. Stavridis, D. Degiannis, and S. Geroulanos Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 629 - 633. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pirracchio, B. Cholley, S. De Hert, A. C. Solal, and A. Mebazaa Diastolic heart failure in anaesthesia and critical care Br. J. Anaesth., June 1, 2007; 98(6): 707 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Pagel Levosimendan in Cardiac Surgery: A Unique Drug for the Treatment of Perioperative Left Ventricular Dysfunction or Just Another Inodilator Searching for a Clinical Application? Anesth. Analg., April 1, 2007; 104(4): 759 - 761. [Full Text] [PDF] |
||||
![]() |
S. G. De Hert, S. Lorsomradee, S. Cromheecke, and P. J. Van der Linden The Effects of Levosimendan in Cardiac Surgery Patients with Poor Left Ventricular Function Anesth. Analg., April 1, 2007; 104(4): 766 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships Circulation, March 13, 2007; 115(10): 1218 - 1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Raja and B. S. Rayen Levosimendan in Cardiac Surgery: Current Best Available Evidence Ann. Thorac. Surg., April 1, 2006; 81(4): 1536 - 1546. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Song, K. Sakurai, T. Nakayama, M. Shirakawa, H. Hagiwara, and H. Kamiya Intracoronary Adenosine Triphosphate for Refractory Coronary Artery Spasm Asian Cardiovasc Thorac Ann, April 1, 2006; 14(2): e21 - e23. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, and J. J. Ferrer-Hita Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST-Elevation Myocardial Infarction: A Series of Cases J. Clin. Pharmacol., June 1, 2005; 45(6): 704 - 708. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |